Phase II multicenter study of adjuvant S-1 for colorectal liver metastasis: Survival analysis of N-SOG 01 trial

Cancer Chemotherapy and Pharmacology

Volumn 75, Issue 6, 2015, Pages 1281-1288

  Kato, Takehiro ^a   Uehara, Keisuke ^a   Maeda, Atsuyuki ^b   Sakamoto, Eiji ^c   Hiramatsu, Kazuhiro ^d   Takeuchi, Eiji ^e   Goto, Hidenari ^f   Tojima, Yuichiro ^g   Yatsuya, Hiroshi ^h   Nagino, Masato ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OGAKI MUNICIPAL HOSPITAL   (Japan)

^c NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^d TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^e JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^f ANJO KOSEI HOSPITAL   (Japan)

^g CHUKYO HOSPITAL   (Japan)

^h FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adjuvant chemotherapy; Colorectal cancer; Liver metastasis; S 1; Survival

Indexed keywords

GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC ANTIMETABOLITE; DRUG COMBINATION; OTERACIL; S 1 (COMBINATION); TEGAFUR;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; COLORECTAL LIVER METASTASIS; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; FATIGUE; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; LIVER RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DRUG COMBINATION; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; SECONDARY; SURVIVAL;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OXONIC ACID; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TEGAFUR;

EID: 84929951290     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2752-5     Document Type: Article

References (29)

1. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology. Colon cancer v.2. (2012) http://www.nccn.org/professionals/physician-gls/pdf/colon.pdf. Accessed 29 August 2014
2. Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007-1016. doi: 10.1016/S0140-6736(08)60455-9
3. Nordlinger B, Sorbye H, Glimelius B et al (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14:1208-1215. doi: 10.1016/S1470-2045(13)70447-9
4. Portier G, Elias D, Bouche O et al (2006) Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24:4976-4982
5. Kanemitsu Y, Kato T, Shimizu Y et al (2009) A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone as treatment for liver metastasis from colorectal cancer: Japan Clinical Oncology Group Study JCOG0603. Jpn J Clin Oncol 39:406-409. doi: 10.1093/jjco/hyp035
6. André T, Boni C, Mounedji-Boudiaf L et al (2004) Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351
7. Kuebler JP, Wieand HS, O'Connell MJ et al (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25:2198-2204
8. Haller DG, Tabernero J, Maroun J et al (2011) Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29:1465-1471. doi: 10.1200/JCO.2010.33.6297
9. Hamaguchi T, Shirao K, Moriya Y et al (2011) Final results of randomized trials by the National Surgical Adjuvant Study of Colorectal Cancer (NSAS-CC). Cancer Chemother Pharmacol 67:587-596. doi: 10.1007/s00280-010-1358-1
10. Watanabe T, Itabashi M, Shimada Y et al (2012) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol 17:1-29. doi: 10.1007/s10147-011-0315-2
11. Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810-1820
12. Mochizuki I, Takiuchi H, Ikejiri K et al (2012) Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial. Br J Cancer 106:1268-1273. doi: 10.1038/bjc.2012.86
13. Yoshida M, Ishiguro M, Ikejiri K et al (2014) S-1 as adjuvant chemotherapy for stage III colon cancer: A randomized phase III study (ACTS-CC trial). Ann Oncol 25:1743-1749. doi: 10.1093/annonc/mdu232
14. Kobayashi A, Hasegawa K, Saiura A et al (2014) A randomized controlled trial evaluating efficacy of adjuvant oral uracil-tegafur (UFT) with leucovorin (LV) after resection of colorectal liver metastases; The UFT/LV study. J Clin Oncol 32:5s (suppl; abstr 3584)
15. Uehara K, Maeda A, Sakamoto E et al (2013) Phase II trial of adjuvant chemotherapy with S-1 for colorectal liver metastasis. Ann Surg Oncol 20:475-481. doi: 10.1245/s10434-012-2665-z
16. Japanese Society for Cancer of the Colon and Rectum (2009) Japanese Classification of Colorectal Carcinoma. Second English Edition. Kanehar, Tokyo
17. Sobin LH, Wittekind Ch (2010) TNM classification of malignant tumours, 6th edn. Wiley-Blackwell, Chichester
18. Rees M, Tekkis PP, Welsh FK, O'Rourke T, John TG (2008) Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 247:125-135
19. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309-318
20. Ueno H, Mochizuki H, Hatsuse K, Hase K, Yamamoto T (2000) Indicators for treatment strategies of colorectal liver metastases. Ann Surg 231:59-66
21. Adam R, Delvart V, Pascal G et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240:644-657
22. Pawlik TM, Scoggins CR, Zorzi D et al (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241:715-722
23. Choti MA, Sitzmann JV, Tiburi MF et al (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 35:759-766
24. Nordlinger B, Van Cutsem E, Gruenberger T et al (2009) Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 20:985-992. doi: 10.1093/annonc/mdn735
25. Adam R, Bhangui P, Poston G et al (2010) Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg 252:774-787. doi: 10.1097/SLA.0b013e3181fcf3e3
26. André T, Iveson T, Labianca R et al (2013) The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) collaboration: prospective combined analysis of phase III trials investigating duration of adjuvant therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) regimen for patients with stage III colon cancer: trial design and current status. Curr Colorectal Cancer Rep 9:261-269
27. Tsuchiya T, Sadahiro S, Sasaki K et al (2014) Safety analysis of two different regimens of uracil-tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial. Cancer Chemother Pharmacol 73:1253-1261. doi: 10.1007/s00280-014-2461-5
28. Kondo K, Sadahiro S, Tsuchiya T et al (2013) Phase III trial of treatment duration for oral uracil and tegafur/leucovorin adjuvant chemotherapy for patients (PTS) with stage IIB/III colon cancer: result of JFMC33-0502. Ann Oncol 23:9s, (abstr 552P)
29. Kunieda K, Sadahiro S, Mishima H et al (2012) Six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III (Dukes' C) colon cancer: Initial safety report for the open-label randomized phase III study (JFMC37-0801). J Clin Oncol 30, (suppl; abstr 3607)